Caprock Group LLC Makes New $6.48 Million Investment in Medtronic PLC $MDT

Caprock Group LLC purchased a new stake in Medtronic PLC (NYSE:MDT) during the third quarter, according to its most recent filing with the SEC. The firm purchased 69,801 shares of the medical technology company’s stock, valued at approximately $6,478,000.

Other large investors have also recently made changes to their positions in the company. Delos Wealth Advisors LLC purchased a new position in Medtronic in the second quarter valued at about $27,000. Corundum Trust Company INC bought a new stake in shares of Medtronic in the 3rd quarter valued at about $27,000. Valley Wealth Managers Inc. purchased a new position in shares of Medtronic in the 3rd quarter worth approximately $29,000. Steigerwald Gordon & Koch Inc. bought a new position in shares of Medtronic during the 3rd quarter worth approximately $33,000. Finally, Tripletail Wealth Management LLC purchased a new stake in Medtronic during the third quarter valued at approximately $34,000. 82.06% of the stock is owned by institutional investors.

Key Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic agreed to acquire CathWorks for $585 million — expands its cath-lab/FFR imaging capabilities and strengthens the cardiovascular franchise, a strategic tuck-in that could accelerate revenue and cross‑sell opportunities. Medtronic to Buy CathWorks for $585M
• Positive Sentiment: Needham upgraded MDT to a “buy” and set a $121 price target (~19% upside from current levels) — the upgrade can attract buying interest and supports near-term sentiment. Needham upgrades Medtronic (MDT)
• Positive Sentiment: Analysts and trade press note new product momentum and related rating boosts — fresh product launches/approvals bolster growth narrative and margin leverage over time. Medtronic stock gets a ratings boost on new products
• Positive Sentiment: Outlook drivers: Zacks highlights strength in Medtronic’s cardiovascular unit as a likely lift to Q3 revenue (projected ~7.3% y/y), which could offset softer EPS. Strength in Cardiovascular Unit Likely to Lift MDT’s Q3 Performance
• Neutral Sentiment: MDT is expected to report earnings this week — the print and any revised FY guidance remain the primary short-term catalyst. Medtronic (MDT) Expected to Announce Earnings on Tuesday
• Neutral Sentiment: Analyst/market narratives are shifting as Medtronic’s strategic moves and pipeline progress get priced in — read for context on repositioning and valuation. How Recent Moves Are Quietly Rewriting The Story For Medtronic (MDT)
• Neutral Sentiment: Market note: the stock recently dipped while broader markets gained — a short-term trading signal but not a fundamental verdict. Medtronic (MDT) Stock Dips While Market Gains: Key Facts
• Negative Sentiment: An antitrust verdict awarded roughly $381.7M in damages against Medtronic — this legal cost and any follow‑on litigation/settlement risk can pressure near‑term earnings and valuation multiples. A Look At Medtronic (MDT) Valuation After Major Antitrust Verdict And US$381.7m Damages Award

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on MDT shares. Royal Bank Of Canada lifted their price target on shares of Medtronic from $111.00 to $118.00 and gave the stock an “outperform” rating in a report on Wednesday, November 19th. The Goldman Sachs Group set a $111.00 price objective on Medtronic and gave the stock a “neutral” rating in a research report on Wednesday, November 19th. Morgan Stanley boosted their target price on Medtronic from $107.00 to $117.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 19th. Needham & Company LLC upgraded Medtronic from a “hold” rating to a “buy” rating and set a $121.00 price target for the company in a research note on Monday. Finally, Jefferies Financial Group reissued a “hold” rating and issued a $110.00 price target on shares of Medtronic in a report on Wednesday, November 19th. Sixteen research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. According to MarketBeat, Medtronic currently has an average rating of “Moderate Buy” and an average target price of $111.21.

Medtronic Stock Performance

Shares of MDT stock opened at $101.37 on Wednesday. The business has a fifty day moving average of $99.36 and a 200 day moving average of $96.28. Medtronic PLC has a 1 year low of $79.55 and a 1 year high of $106.33. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.42 and a quick ratio of 1.80. The firm has a market capitalization of $129.96 billion, a price-to-earnings ratio of 27.32, a price-to-earnings-growth ratio of 2.68 and a beta of 0.71.

Medtronic (NYSE:MDT) last posted its quarterly earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share for the quarter, beating the consensus estimate of $1.31 by $0.05. The business had revenue of $8.96 billion for the quarter, compared to the consensus estimate of $8.86 billion. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The company’s quarterly revenue was up 6.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.26 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, research analysts expect that Medtronic PLC will post 5.46 earnings per share for the current year.

Medtronic Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, January 16th. Investors of record on Friday, December 26th were issued a $0.71 dividend. This represents a $2.84 annualized dividend and a yield of 2.8%. The ex-dividend date was Friday, December 26th. Medtronic’s dividend payout ratio is 76.55%.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).